Skip to main content
TipRanks
Go Ultimate75% OFF

Vicore Pharma Holding AB Sponsored ADR (VCRE) AI Stock Analysis

3 Followers
VCRE

Vicore Pharma Holding AB Sponsored ADR

(NASDAQ:VCRE)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Vicore Pharma Holding AB Sponsored ADR (VCRE) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%VCRE-26.47%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$279.65M
Dividend Yield
―
Average Volume (3M)
23.28K
Price to Earnings (P/E)
-5.5
Beta (1Y)
0.55
Revenue Growth
-50.05%
EPS Growth
-9.20%
Country
US
Employees
37
Sector
General
Sector Strength
55
Industry
Biotechnology

Vicore Pharma Holding AB Sponsored ADR Business Overview & Revenue Model

Company Description

Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clin...

Vicore Pharma Holding AB Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

VCRE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
QTTBQTTB55Neutral$258.24M2.7326.77%―――
KROSKROS51Neutral$235.49M-4.27-21.85%―-83.48%-277.31%
UPBUPB43Neutral$114.01M-0.69-57.09%―2.54%-31.89%
CRBPCRBP40Underperform$62.03M-0.43-100.96%――-10.49%
GALTGALT40Underperform$293.55M-8.8421.65%――42.26%

* General Sector Average

Performance Comparison

0%250%500%750%1000%VCREGALTCRBPQTTBKROSUPBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VCRE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VCREVicore Pharma Holding AB Sponsored ADR9.90-3.56-26.47%
GALTGalectin Therapeutics (GALT)2.98-2.76-48.08%
CRBPCorbus Pharmaceuticals Holdings2.75-8.95-76.52%
QTTBQ32 Bio Inc8.536.60341.97%
KROSKeros Therapeutics, Inc.12.00-4.82-28.66%
UPBUpstream Bio, Inc.2.08-22.88-91.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.